(MedPage Today) — Last week marked the FDA’s deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some patients unsure where to turn next. (NPR) Dexcom’s investigational 15-day G7 integrated continuous glucose… Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/114813 Author : Publish date : 2025-03-25 17:13:00 Copyright for syndicated content belongs to the linked Source.
The post Curtains for Tirzepatide Compounding; Redefining Obesity; Menopause and Salary first appeared on News Health.
Author : News Health
Publish date : 2025-03-25 17:13:00
Copyright for syndicated content belongs to the linked Source.